CHMP recommendation based on safety, tolerability, and immunogenicity data from a Phase 2/3 trial of the Omicron BA.1-adapted bivalent vaccine
Phase 2 study to assess efficacy and safety of once daily linperlisib in patients with advanced peripheral T/NK cell lymphoma
The integrated capabilities at Unit 2 offer significant operational flexibility, greater efficiency, and varied scope within the same premise
On the precision oncology front, expanded larotrectinib data will focus on efficacy and safety findings for pediatric and adult patients with NTRK gene fusion-positive solid tumors
India is at the forefront of research in cardiology worldwide but making indigenous products is what we are lacking & it needs to be improved
Subject Expert Committee(SEC) of Central Drugs Standard Control Organization (CDSCO)
This launch builds upon Hikma’s leading position as one of the largest US providers of nasally administered medicines used for treating seasonal allergies and advances its objective of growing its specialty business in the US
Indonesia national agency for drug and food control, BPOM, approved QDENGA for use in individuals 6 to 45 years of age
Pending authorization, Moderna ready to ship bivalent booster mRNA-1273.222 in September
Lutio has the potential to offer significant cost savings when available to UK patients.
Subscribe To Our Newsletter & Stay Updated
